Vertex Pharmaceuticals (VRTX) Retained Earnings: 2009-2025
Historic Retained Earnings for Vertex Pharmaceuticals (VRTX) over the last 16 years, with Sep 2025 value amounting to $12.4 billion.
- Vertex Pharmaceuticals' Retained Earnings rose 42.27% to $12.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $12.4 billion, marking a year-over-year increase of 42.27%. This contributed to the annual value of $9.6 billion for FY2024, which is 5.28% down from last year.
- Latest data reveals that Vertex Pharmaceuticals reported Retained Earnings of $12.4 billion as of Q3 2025, which was up 9.60% from $11.3 billion recorded in Q2 2025.
- Vertex Pharmaceuticals' 5-year Retained Earnings high stood at $12.4 billion for Q3 2025, and its period low was $1.5 billion during Q1 2021.
- Moreover, its 3-year median value for Retained Earnings was $9.6 billion (2024), whereas its average is $9.6 billion.
- Its Retained Earnings has fluctuated over the past 5 years, first skyrocketed by 855.15% in 2021, then dropped by 8.80% in 2025.
- Vertex Pharmaceuticals' Retained Earnings (Quarterly) stood at $3.2 billion in 2021, then surged by 103.79% to $6.5 billion in 2022, then surged by 55.49% to $10.1 billion in 2023, then decreased by 5.28% to $9.6 billion in 2024, then soared by 42.27% to $12.4 billion in 2025.
- Its Retained Earnings was $12.4 billion in Q3 2025, compared to $11.3 billion in Q2 2025 and $10.3 billion in Q1 2025.